• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    12/22/23 12:31:08 PM ET
    $ALVR
    $BACK
    $BEAT
    $CYCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities
    Health Care
    Get the next $ALVR alert in real time by email

    Gainers

    • Jin Medical International (NASDAQ:ZJYL) shares rose 85.2% to $130.55 during Friday's regular session. The company's market cap stands at $1.0 billion.
    • Karuna Therapeutics (NASDAQ:KRTX) stock increased by 47.07% to $316.5. The market value of their outstanding shares is at $11.9 billion.
    • IMAC Hldgs (NASDAQ:BACK) shares rose 35.8% to $2.2. The market value of their outstanding shares is at $2.5 million.
    • PureTech Health (NASDAQ:PRTC) shares increased by 28.15% to $24.4. The company's market cap stands at $663.5 million.
    • HeartBeam (NASDAQ:BEAT) stock moved upwards by 24.84% to $2.07. The company's market cap stands at $54.5 million.
    • Neumora Therapeutics (NASDAQ:NMRA) shares increased by 23.73% to $17.31. The company's market cap stands at $2.6 billion.

    Losers

    • AlloVir (NASDAQ:ALVR) shares fell 65.7% to $0.8 during Friday's regular session. The company's market cap stands at $91.2 million.
    • Cyclacel Pharmaceuticals (NASDAQ:CYCC) shares fell 22.09% to $2.81. The market value of their outstanding shares is at $2.3 million.
    • 60 Degrees (NASDAQ:SXTP) shares decreased by 20.46% to $0.88. The company's market cap stands at $5.0 million.
    • Nanobiotix (NASDAQ:NBTX) shares decreased by 11.98% to $6.76. The market value of their outstanding shares is at $318.4 million.
    • Trinity Biotech (NASDAQ:TRIB) stock declined by 10.96% to $0.4. The company's market cap stands at $15.3 million.
    • GRI Bio (NASDAQ:GRI) shares decreased by 10.54% to $0.33. The company's market cap stands at $1.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALVR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALVR
    $BACK
    $BEAT
    $CYCC

    CompanyDatePrice TargetRatingAnalyst
    Neumora Therapeutics Inc.
    $NMRA
    2/17/2026Mkt Perform → Outperform
    William Blair
    Nanobiotix S.A.
    $NBTX
    2/6/2026Buy
    TD Cowen
    Neumora Therapeutics Inc.
    $NMRA
    1/12/2026$8.00Outperform
    Leerink Partners
    Heartbeam Inc.
    $BEAT
    12/11/2025$8.00Speculative Buy → Buy
    The Benchmark Company
    Heartbeam Inc.
    $BEAT
    12/8/2025$2.50Buy
    H.C. Wainwright
    Neumora Therapeutics Inc.
    $NMRA
    12/1/2025$7.00Sector Perform → Outperform
    RBC Capital Mkts
    Heartbeam Inc.
    $BEAT
    10/31/2025$4.00Buy
    Roth Capital
    Neumora Therapeutics Inc.
    $NMRA
    10/27/2025$14.00Neutral → Buy
    Guggenheim
    More analyst ratings

    $ALVR
    $BACK
    $BEAT
    $CYCC
    SEC Filings

    View All

    SEC Form 424B5 filed by 60 Degrees Pharmaceuticals Inc.

    424B5 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

    3/2/26 4:20:12 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IMAC Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - IMAC Holdings, Inc. (0001729944) (Filer)

    2/27/26 4:00:35 PM ET
    $BACK
    Medical Specialities
    Health Care

    SEC Form 6-K filed by Nanobiotix S.A.

    6-K - Nanobiotix S.A. (0001760854) (Filer)

    2/25/26 4:15:03 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALVR
    $BACK
    $BEAT
    $CYCC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Neumora Therapeutics upgraded by William Blair

    William Blair upgraded Neumora Therapeutics from Mkt Perform to Outperform

    2/17/26 7:22:19 AM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TD Cowen initiated coverage on Nanobiotix

    TD Cowen initiated coverage of Nanobiotix with a rating of Buy

    2/6/26 8:11:18 AM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Neumora Therapeutics with a new price target

    Leerink Partners initiated coverage of Neumora Therapeutics with a rating of Outperform and set a new price target of $8.00

    1/12/26 8:18:29 AM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALVR
    $BACK
    $BEAT
    $CYCC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NANOBIOTIX to Participate in Investor Conferences in March

    PARIS and CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ:NBTX - the "Company"), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in these upcoming conferences in March: TD Cowen's Health Care ConferenceDate: Wednesday, March 4, 2026Location: Boston, MATime of the fireside chat: 11:10am ET / 5:10pm CETPresenters: Laurent Levy, Chief Executive Officer of Nanobiotix and Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix UBS Biotech Summit Miami Date: Monday, March

    2/25/26 4:15:00 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Trinity Biotech Secures $25 Million Financing Commitment to Support Growth Initiatives

    - Agreement provides additional funding tool of up to $25 million over a period of up to 36 months - Underpins the Company's ambitions to expand its commercialisation activities and advance its innovation agenda DUBLIN, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has entered into a $25 million Standby Equity Purchase Agreement ("SEPA") with an affiliate of financing partner Yorkville Advisors Global ("Yorkville"). The agreement provides Trinity Biotech with an additional funding tool designed to augment th

    2/25/26 9:00:00 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    PureTech to Present at the Leerink Partners Global Healthcare Conference

    PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announced that Robert Lyne, Chief Executive Officer, and Eric Elenko, PhD, Co-founder and President, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Wednesday, March 11, 2026, at 11:20am EDT. A webcast of the presentation will be available at https://investors.puretechhealth.com. About PureTech Health PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. We do this thr

    2/25/26 2:00:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALVR
    $BACK
    $BEAT
    $CYCC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Aurora Daljit Singh sold $21,917 worth of shares (6,165 units at $3.56), decreasing direct ownership by 7% to 82,770 units (SEC Form 4)

    4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)

    2/19/26 5:07:13 PM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President Pinto Joshua sold $21,093 worth of shares (5,967 units at $3.54), decreasing direct ownership by 9% to 57,783 units (SEC Form 4)

    4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)

    2/19/26 5:06:16 PM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Berns Paul L sold $34,459 worth of shares (9,819 units at $3.51), decreasing direct ownership by 0.13% to 7,395,185 units (SEC Form 4)

    4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)

    2/19/26 5:05:16 PM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALVR
    $BACK
    $BEAT
    $CYCC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Dow Geoffrey S bought $7,759 worth of shares (9,670 units at $0.80), increasing direct ownership by 19% to 59,618 units (SEC Form 4)

    4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

    12/16/25 5:41:35 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Dow Geoffrey S bought $12,204 worth of shares (12,963 units at $0.94), increasing direct ownership by 35% to 49,948 units (SEC Form 4)

    4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

    12/12/25 8:39:45 AM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Burow Kristina bought $4,999,977 worth of shares (1,915,700 units at $2.61) (SEC Form 4)

    4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)

    10/29/25 7:22:24 PM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALVR
    $BACK
    $BEAT
    $CYCC
    Leadership Updates

    Live Leadership Updates

    View All

    HeartBeam Appoints Bryan Humbarger as Chief Commercial Officer

    Brings more than 25 years of experience in building and scaling groundbreaking cardiovascular technologies Will initially focus on launching the Company's FDA-cleared 12-lead ECG system for arrhythmia assessment Will lead the Company's broader commercialization strategy across key growth initiatives, including heart attack detection and the 12-lead ECG extended-wear patch HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced the appointment of Bryan Humbarger as Chief Commercial Officer, effective January 22, 2026. In this newly created role, Mr. Humbarger will lead commercial strate

    1/22/26 7:00:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    PureTech Appoints Robert Lyne as Chief Executive Officer

    PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announces that the Board of Directors has appointed Robert Lyne as Chief Executive Officer (CEO), and as a member of the Board of Directors, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251217152848/en/Robert Lyne, Chief Executive Officer of PureTech Robert Lyne commented: "I'm honored to lead PureTech as CEO at such an important moment in its evolution. Over the past two years, I've seen first-hand the streng

    12/18/25 2:00:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris

    PARIS and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) --  NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that following the annual review of the Euronext Paris indices, the Scientific Council of the Indices has decided to admit Nanobiotix to both the CAC Mid 60 and SBF 120 indices. These changes will become effective after the market closes on Friday, December 19, 2025. The CAC Mid 60 and SBF 120 indices represent two of the most widely followed benchmarks for mid-sized and leading liste

    12/15/25 2:30:00 AM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALVR
    $BACK
    $BEAT
    $CYCC
    Financials

    Live finance-specific insights

    View All

    Trinity Biotech Secures $25 Million Financing Commitment to Support Growth Initiatives

    - Agreement provides additional funding tool of up to $25 million over a period of up to 36 months - Underpins the Company's ambitions to expand its commercialisation activities and advance its innovation agenda DUBLIN, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has entered into a $25 million Standby Equity Purchase Agreement ("SEPA") with an affiliate of financing partner Yorkville Advisors Global ("Yorkville"). The agreement provides Trinity Biotech with an additional funding tool designed to augment th

    2/25/26 9:00:00 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares

    DUBLIN, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, received notice on February 19, 2026 from the Nasdaq Stock Market LLC ("Nasdaq") that the Company no longer meets the requirement in Nasdaq Listing Rule 5450(b) that listed securities maintain a minimum market value of publicly held shares ("MVPHS") of $15,000,000, based on Nasdaq's review of the Company's MVPHS for the last 30 consecutive business days. This notice has no immediate effect on the listing of the Company's ADSs, which will continue to trade at this time on the Nas

    2/20/26 5:00:00 PM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Nasdaq Minimum Bid Price Requirement

    DUBLIN, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, received notice on February 11, 2026 from the Nasdaq Stock Market LLC ("Nasdaq") that the Company is not in compliance with Nasdaq Listing Rule 5450(a)(1), requiring that listed securities maintain a minimum bid price of $1.00 per share, based on the closing bid price of the Company's American Depositary Shares ("ADSs") for the last 30 consecutive business days. This notice has no immediate effect on the listing of the Company's ADSs, which will continue to trade at this time on

    2/13/26 5:00:00 PM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ALVR
    $BACK
    $BEAT
    $CYCC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Neumora Therapeutics Inc.

    SC 13D/A - Neumora Therapeutics, Inc. (0001885522) (Subject)

    11/22/24 5:33:43 PM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cyclacel Pharmaceuticals Inc.

    SC 13G/A - Cyclacel Pharmaceuticals, Inc. (0001130166) (Subject)

    11/14/24 7:21:58 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Trinity Biotech plc

    SC 13D/A - TRINITY BIOTECH PLC (0000888721) (Subject)

    11/14/24 5:26:28 PM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care